Anticoagulants Clinical Trial
Official title:
Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence in Patients With Atrial Fibrillation: A Randomized Controlled Trial
Verified date | August 2021 |
Source | National Taipei University of Nursing and Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Inconsistent anticoagulation therapy in AF patients is associated with a higher risk of stroke and abnormal bleeding. The purpose of the study is to investigate the efficacy of a health belief model based self-management of oral anticoagulant therapy intervention on the outcome of medication adherence and the mediators of knowledge, professional support, health belief, and self-efficacy in patients treated with oral anticoagulants for atrial fibrillation. A randomized clinical trial with repeated measurements was conducted. A convenient sample of 110 adults who were treated with anticoagulants for atrial fibrillation was recruited from two teaching hospitals in northern Taiwan. Participants were randomly assigned 1:1 to either the control group (n = 36) or the intervention group (n = 36) after completion of baseline questionnaires. Patients in the experimental group received the health belief model based anticoagulation adherence intervention, including one 60-minute individual instructions and six 15-minute telephone follow-ups. Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health. Patients in both groups answered the study questionnaires at three and six months. The generalized estimating equations were used to analyze the efficacy of the intervention for enhancing knowledge, knowledge, perceived benefits, perceived barriers, self-efficacy, and adherence to anticoagulant therapies in patients treated with oral anticoagulants for atrial fibrillation. The results of the study will contribute to the knowledge for improving adherence to oral anticoagulation therapies in patients with atrial fibrillation.
Status | Completed |
Enrollment | 72 |
Est. completion date | October 20, 2017 |
Est. primary completion date | April 20, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: 1. = 20 years of age 2. fluent in Mandarin or Taiwanese 3. diagnosed with AF 4. treated with warfarin or NOACs for anticoagulation. Exclusion Criteria: 1. diagnosed with psychological diseases 2. diagnosed with uncontrolled hypertension 3. diagnosed with the New York Heart Association (NYHA) grade VI heart failure 4. implanted with a cardiac pacemaker 5. had cardiac surgery in the past three months 6. hospitalized for AF in the past three months. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Taipei Medical University WanFang Hospital | Taipei | |
Taiwan | Taipei Medical University Shuang Ho Hospital | Taipei county | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taipei University of Nursing and Health Sciences | Taipei Medical University Shuang Ho Hospital, Taipei Medical University WanFang Hospital |
Taiwan,
Chiang CE, Wu TJ, Ueng KC, Chao TF, Chang KC, Wang CC, Lin YJ, Yin WH, Kuo JY, Lin WS, Tsai CT, Liu YB, Lee KT, Lin LJ, Lin LY, Wang KL, Chen YJ, Chen MC, Cheng CC, Wen MS, Chen WJ, Chen JH, Lai WT, Chiou CW, Lin JL, Yeh SJ, Chen SA. 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. J Formos Med Assoc. 2016 Nov;115(11):893-952. doi: 10.1016/j.jfma.2016.10.005. Epub 2016 Nov 24. — View Citation
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28. Review. Erratum in: J Am Coll Cardiol. 2014 Dec 2;64(21):2305-7. — View Citation
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castellá M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Alexandru Popescu B, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Rev Esp Cardiol (Engl Ed). 2017 Jan;70(1):50. doi: 10.1016/j.rec.2016.11.033. English, Spanish. Erratum in: Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):1031. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The Satisfaction Scale About Service and Warfarin Treatment (SSWT) | The original scale includes seven positive statements about the services and warfarin treatment. In the current study, the term of warfarin was replaced with anticoagulants. The item 5 (regarding INR monitoring) in the original scale was deleted as it only applies to patients treated with warfarin. Therefore, there were only six items used in the current study. For each item, the subjects indicated their levels of agreement on a 5-point Likert scale (from 0_ strongly disagree to 4_ strongly agree). The total score of the 6 items represents the scale score, with a possible range of 0 to 24. Higher scores indicate higher levels of satisfaction about service and warfarin treatment. | baseline (T1), 12th week (T2), and 24th week (T3) follow-ups | |
Primary | The Short-form Adherence to Re?lls and Medications Scale (ARMS) | There are seven items in the scale. Subjects were asked to indicate how often they actually miss taking their anticoagulants in each item on a 4-point Likert scale (1_ none of the time to 4_ all of the time). The total score of the 7 items represents the scale score, with a possible range of 7 to 28. A higher score indicates worse adherence to anticoagulation treatment. | baseline (T1), 12th week (T2), and 24th week (T3) follow-ups. | |
Secondary | The Knowledge of Warfarin Anticoagulation Treatment Scale | The 11-item scale covers four areas of warfarin treatment knowledge: administration (e.g., dose, color, and route of administration), interaction with foods, interaction with other drugs, and side effects. There are five choices for each item, and only one of the choices is correct (scored 1). The total score of the 11 items represents the scale score, with a possible range of 0 to 11. Higher scores indicate higher levels of understanding of warfarin treatment. The scale was also modified to measure the NOACs treatment knowledge. To facilitate analysis and comparison, the score of each scale was converted to a scale of 0 to 100 (actual score/possible maximum score x 100). | baseline (T1), 12th week (T2), and 24th week (T3) follow-ups. | |
Secondary | The Perceived Benefits Subscale of the Beliefs About Anticoagulation Survey (BAAS) | The subscale covers 5 potential benefits of taking anticoagulation, including lessening the risk of having a stroke, lowering the chance of being hospitalized, feeling healthier, improving quality of life, and worrying less about the disease. For each item, the subjects indicated their levels of agreement on a 5-point Likert scale (from 1_ strongly disagree to 5_ strongly agree). The potential scores range from 5 to 25 points, with higher scores indicating higher levels of perceived benefits associated with taking anticoagulation. | baseline (T1), 12th week (T2), and 24th week (T3) follow-ups. | |
Secondary | The Concerns About Anticoagulation Therapy Scale | The scale lists ten potential concerns, including drug interactions, forgetting to take anticoagulants, side effects, hospital visits, diet interactions, activity restrictions, impact on work, not helpful, and difficulty of following instructions. The subjects were asked to indicate all concerns that apply to them. Each concern was scored 1. The potential scores range from 0 to 10, with higher scores indicating more concerns. | baseline (T1), 12th week (T2), and 24th week (T3) follow-ups. | |
Secondary | The Self-efficacy for Appropriate Medication Use Scale (SEAMS) | The 13-item scale covers two dimensions of self-efficacy: for taking medications under difficult circumstances and for taking medications under uncertain or changing circumstances. For each item, the subjects indicated their level of confidence about taking medications correctly under a specific circumstance on a three-point response scale (1 _ not confident, 2 _ somewhat confident, and 3 _ very confident). The potential scores range from 13 to 39, with high scores indicating higher levels of self-efficacy for appropriate anticoagulant use. | baseline (T1), 12th week (T2), and 24th week (T3) follow-ups. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02128841 -
Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
|
Phase 2 | |
Recruiting |
NCT03666962 -
Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation
|
||
Recruiting |
NCT03670446 -
Pharmacists' Intervention in Patients Using Novel Oral Anticoagulants:A Study on Behavioral Patterns
|
N/A | |
Recruiting |
NCT04796714 -
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
|
Phase 4 | |
Completed |
NCT01033279 -
Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy
|
N/A | |
Completed |
NCT00287313 -
Daily Vitamin K in Patients on Warfarin With Unstable INRs
|
N/A | |
Completed |
NCT00222638 -
Influenza Vaccination and Oral Anticoagulant Therapy
|
Phase 4 | |
Active, not recruiting |
NCT06203795 -
Dialysis Performance of the FX CorAL Membrane
|
N/A | |
Active, not recruiting |
NCT06401863 -
Shared Decision for Drug Interactions in Oral Anticoagulation
|
N/A | |
Not yet recruiting |
NCT04977076 -
Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention
|
N/A | |
Recruiting |
NCT04861103 -
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
|
Phase 4 | |
Completed |
NCT01653405 -
Improving Anticoagulation Control in VISN 1
|
N/A | |
Not yet recruiting |
NCT05820854 -
Self-care and Self-efficacy Scale in Oral Anticoagulation Therapy
|
||
Completed |
NCT04681482 -
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
|
||
Not yet recruiting |
NCT06137794 -
Application of "I-Anticoagulation"in Patients With Atrial Fibrillation
|
N/A | |
Completed |
NCT02103101 -
Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events
|
N/A | |
Completed |
NCT05065502 -
MIDAS Cluster Randomized Controlled Trial of Implementation Strategies to Optimize Use of Medications in VA Clinical Settings
|
N/A | |
Recruiting |
NCT03965208 -
Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation
|
Phase 4 | |
Completed |
NCT03318393 -
Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO
|
Phase 4 | |
Recruiting |
NCT03288441 -
Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
|